Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Anticholinergics, tiotropium, ACs
Ipratropium · 2 trials · 1 indication
To correlate changes in oxygen saturation pre- and post- bronchodilator (as a reflection of ventilation/perfusion matching) with changes in distribution of regional ventilation/perfusion (V/Q) demonstrated by hyperpolarized helium ventilation MRI/spatially registered proton perfusion.
To correlate changes in oxygen saturation pre- and post- bronchodilator (as a reflection of ventilation/perfusion matching) with changes in distribution of regional ventilation/perfusion (V/Q) demonstrated by hyperpolarized helium ventilation MRI/spatially registered proton perfusion.
| Arm | Type | Description |
|---|---|---|
| Salbutamol + Ipratropium | OTHER | Treatment period 1: Salbutamol 5mg nebulised, single Dose. Treatment period 2: Ipratropium 500mcg nebulised, single dose. |
| Ipratropium + Salbutamol | OTHER | Treatment period 1: Ipratropium 500mcg nebulised, single dose. Treatment period 2: Salbutamol 5mg nebulised, single Dose. |
| Propranolol alone | EXPERIMENTAL | Propranolol 80 mg (5 doses at 6 hourly intervals) |
| Propranolol + salbutamol | EXPERIMENTAL | Propranolol 80 mg (5 doses at 6 hourly intervals) + salbutamol 600 μg (4 doses at 6 hourly intervals) |
| Salbutamol alone | EXPERIMENTAL | Salbutamol 600 μg (4 doses at 6 hourly) + placebo (5 doses at 6 hourly intervals) |
| Placebo | PLACEBO_COMPARATOR | Placebo (5 doses at 6 hourly) |
| Propranolol + ipratropium + salbutamol | EXPERIMENTAL | Propranolol 80 mg (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose) |
| Placebo + ipratropium + salbutamol | EXPERIMENTAL | Placebo (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose) |
| Name | Type | Description |
|---|---|---|
| He-3 MRI | DEVICE | Hyperpolarised helium-3 Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed). |
| Salbutamol | DRUG | Salbutamol 5mg nebulised single dose |
| Ipratropium | DRUG | Ipratropium 500mcg nebulised single dose |
| MRI | DEVICE | Proton Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed). |
| Propranolol | DRUG | 40 mg tablets |
| Placebo | DRUG | Placebo for propranolol tablets |
Inclusion Criteria: \- Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) diagnosis: an established clinical history of chronic pulmonary disorder in accordance with the following description by the American Thoracic Society / European Respiratory Society \[ATS / ETS, 2004\] Chronic obstruc...
Ipratropium is studied in chronic obstructive pulmonary disease (COPD), a respiratory condition. The clinical program described here covers Phase 1 research in COPD, including imaging and pharmacology studies conducted in the United Kingdom. It is an investigational agent in this dataset rather than a marketed therapy for the indication listed.
Ipratropium targets CHRM3, the muscarinic acetylcholine receptor M3, and acts as an antagonist at that receptor. By blocking CHRM3, it interferes with cholinergic signaling in the airways. This target class, an antagonist of a muscarinic receptor, is consistent with its development in respiratory disease.
Ipratropium is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor associated with the clinical development program for this asset in chronic obstructive pulmonary disease.
Ipratropium is in Phase 1 development for chronic obstructive pulmonary disease. The program includes two completed Phase 1 trials with a combined enrollment of 29 participants. Both studies were randomized, double-blind, and controlled, and both have been completed.
Ipratropium has been evaluated in two completed Phase 1 trials: NCT02207452, a helium-3 MRI imaging study in COPD with 11 participants in the United Kingdom, and NCT00549120, a study optimizing the propranolol block model with 18 participants, also in the United Kingdom. Both trials are completed.